Related Experiment Video

Updated: Jun 22, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion

J A Franciosa, G Pierpont, J N Cohn

    Annals of Internal Medicine
    |April 1, 1977
    PubMed

    Insights

    Hydralazine effectively treats left ventricular failure by improving cardiac output and reducing blood pressure. This vasodilator offers benefits comparable to nitroprusside, suggesting its utility in managing chronic heart failure.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Left ventricular failure (LVF) is a critical condition often caused by cardiomyopathy.
    • Effective management of LVF requires agents that improve cardiac function and reduce hemodynamic load.

    Purpose of the Study:

    • To evaluate the hemodynamic effects of hydralazine in patients with LVF.
    • To compare hydralazine's efficacy against nitroprusside in this patient population.

    Main Methods:

    • 16 patients with cardiomyopathy-induced LVF received single oral doses of hydralazine (50-100 mg).
    • Hemodynamic parameters including cardiac output, arterial pressures, and heart rate were monitored.
    • A comparative analysis was performed against data from nitroprusside infusion in the same patients.

    Main Results:

    • Hydralazine significantly increased cardiac output and reduced arterial and pulmonary arterial pressures for at least 4 hours.
    • Compared to nitroprusside, hydralazine showed a similar reduction in systemic vascular resistance but a greater increase in cardiac index.
    • Hydralazine resulted in a lesser decrease in mean arterial pressure, mean pulmonary arterial pressure, and pulmonary wedge pressure than nitroprusside.

    Conclusions:

    • Hydralazine demonstrates significant hemodynamic benefits in patients with left ventricular failure.
    • Its efficacy in improving cardiac output and reducing vascular resistance suggests it is a potentially useful agent for chronic LVF treatment.

    More Related Videos

    Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension09:23

    Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

    Published on: February 11, 2017

    Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans08:21

    Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

    Published on: July 21, 2023

    Related Concept Videos

    Antihypertensive Drugs: Vasodilators01:23

    Antihypertensive Drugs: Vasodilators

    Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure VII: Nursing Interventions01:30

    Heart Failure VII: Nursing Interventions

    The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...